Key result
A review of 16 case reports, 2 longitudinal studies, and 3 clinical trials found that edetate sodium (EDTA) chelation therapy is ineffective for treating atherosclerosis.
Why the study?
Does edetate sodium chelation therapy improve outcomes in patients with atherosclerosis?
Does edetate sodium chelation therapy improve outcomes in patients with atherosclerosis?
EDTA chelation therapy lacks valid scientific evidence for efficacy and should not be used in clinical practice to treat atherosclerosis.
Answers are grounded in this paper and cite their sources.
EDTA chelation should not be used for atherosclerosis; confirms lack of efficacy across reviewed trials and studies.
OBJECTIVE: To determine the safety and efficacy of edetate sodium (ethylenediamine tetraacetic acid; EDTA) chelation therapy for atherosclerosis. METHODS: Literature search using MEDLINE, encompassing 1966 through May 1993. Further references were obtained from articles and books, and from citations obtained from the American Academy of Medical Preventics. RESULTS: 16 case reports or case series, 2 longitudinal studies, and 3 clinical trials were reviewed, along with testimonials cited in 19 books. CONCLUSIONS: Little valid scientific evidence is available. Although the postulated mechanisms of action for EDTA are biologically plausible and EDTA appears to be safe, it has not been proven effective. Indeed, the best evidence shows it to be ineffective. Therefore, EDTA chelation therapy should not be used in clinical practice to treat atherosclerosis.
No takes yet. Share an insight, caveat, or question.
Grier et al. (1993) conducted a review in atherosclerosis. edetate sodium (EDTA) chelation therapy was evaluated on safety and efficacy. A review of 16 case reports, 2 longitudinal studies, and 3 clinical trials found that edetate sodium (EDTA) chelation therapy is ineffective for treating atherosclerosis.
Synapse has enriched 10 related papers. Consider them for comparative context: